There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Verona Pharma Plc (NASDAQ:VRNA) and Aduro BioTech (NASDAQ:ADRO) with bullish sentiments.
Verona Pharma Plc (VRNA)
Wedbush analyst Liana Moussatos reiterated a Buy rating on Verona Pharma Plc today and set a price target of $56. The company’s shares closed on Friday at $13.22.
According to TipRanks.com, Moussatos is a 3-star analyst with an average return of 2.5% and a 42.0% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Global Blood Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Verona Pharma Plc with a $56 average price target.
See today’s analyst top recommended stocks >>
Aduro BioTech (ADRO)
Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Aduro BioTech today. The company’s shares opened today at $5.40, close to its 52-week low of $5.15.
According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 10.4% and a 41.3% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aduro BioTech with a $17.50 average price target, representing a 224.1% upside. In a report issued on August 1, Oppenheimer also assigned a Buy rating to the stock with a $13 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
